Passage Bio Inc Dossier
Qualitative Analysis
Business overview
Passage BIO, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company dedicated to developing one-time, transformative adeno-associated virus (AAV)-based gene therapies for rare and neurodegenerative central nervous system (CNS) diseases. The company's lead clinical product candidate is PBFT02, a gene replacement therapy utilizing an AAV1 capsid to deliver a functional granulin (GRN) gene encoding progranulin (PGRN) to the brain via intra cisterna magna (ICM) administration. PBFT02 is primarily being developed to treat frontotemporal dementia caused by progranulin deficiency (FTD-GRN). Historically, the company co-developed therapies for infantile GM1 gangliosidosis (PBGM01) and Krabbe disease (PBKR03), but has strategically shifted its focus toward adult neurodegenerative disorders.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiated a formal process to explore strategic alternatives to maximize shareholder value, including potential mergers, acquisitions, reverse mergers, asset sales, or strategic partnerships.
Expected impact: Aims to secure the necessary funding or corporate structure to advance clinical assets under more stringent regulatory requirements.
Implementing a major workforce reduction of approximately 75% (affecting about 18 employees) and terminating the lease for its 37,000 square foot office space at 2005 Market Street in Philadelphia.
Expected impact: Significantly reduces operating expenses and non-study overhead, extending the cash runway into mid-2027.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Covered preclinical and IND-enabling work for the Huntington's disease program and a paused Temporal Lobe Epilepsy program, with options on four additional CNS indications.
Terms: Passage Bio provided written notice of termination on May 21, 2026, to narrow partnered pipeline optionality and conserve capital.